Skip to main content
. Author manuscript; available in PMC: 2016 Sep 10.
Published in final edited form as: Cell. 2015 Sep 10;162(6):1242–1256. doi: 10.1016/j.cell.2015.08.052

Figure 7. Analysis of p-S6 expression in tumor biospecimens obtained from patients with advanced-stage melanoma undergoing anti-PD-1 antibody therapy.

Figure 7

(A) Expression of phospho (p)-S6 ribosomal protein by melanoma cells in tumor biospecimens obtained from n=11 patients with stage IV melanoma before treatment start compared to that in patient-matched progressive lesions sampled after initiation of anti-PD-1 antibody therapy. p-S6 expression by melanoma cells was determined by immunohistochemical analysis and graded by three independent investigators blinded to the study outcome on a scale of 0–4 (0: no p-S6 expression by melanoma cells; 1: p-S6 expression in 1–25%; 2: 26–50%; 3: 51–75%; 4: >75% of melanoma cells). (B) Representative p-S6 immunohistochemistry of tumor biospecimens obtained from melanoma patients before initiation with systemic anti-PD-1 antibody therapy showing low (<25%) vs. high (>25%) melanoma cell expression of p-S6. Size bars, 50μm. (C) Kaplan-Meier estimates of progression-free survival and (D) of overall survival probability in stage IV melanoma patients (n=34) demonstrating low (<25%, n=14 patients) vs. high melanoma cell-expression of p-S6 (>25%, n=20 patients) in tumor biospecimens obtained before initiation of systemic anti-PD-1 antibody treatment. See also Table S2.